Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice

Journal of Neurosurgery

Volumn 94, Issue 2, 2001, Pages 287-292

  Deshmukh, P ^a   Glick, R P ^a   Lichtor, T ^a   Moser, R ^a   Cohen, E P ^a  

^a Jr Hospital of Cook County   (United States)

Author keywords

Brain neoplasm; Breast cancer; Gene therapy; Interleukin 2; Mouse; Tumor vaccine

Indexed keywords

CANCER VACCINE; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FRONTAL LOBE; GENE THERAPY; GENETIC TRANSFECTION; HISTOPATHOLOGY; LYMPHOCYTIC INFILTRATION; MEDIATOR RELEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034864743     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2001.94.2.0287     Document Type: Article

References (34)

1. Intratumoral LAK cell and interleukin-2 therapy of human gliomas
2. Hypoprothrombinemia associated with interleukin-2 therapy: Correction with vitamin K
3. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors
4. A new dominant hybrid selective marker for higher eukaryotic cells
5. Human brain tumor-derived cell lines: Growth rate reduced by human fibroblast interferon
6. Treatment of breast cancer with fibroblasts transfected with DNA from breast cancer cells
7. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene
8. Expression of MAGE and BAGE genes in Japanese breast cancers
9. d into a human colon cancer cell line (HCT)
10. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma
11. Development of a new mouse brain tumor model using implantatable micro-cannulas
12. Manipulation of metastasis and tumour growth by transfection with histocompatibility class I genes
13. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells
14. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene
15. A randomized double blind comparison of the antiemetic efficacy of ondansetron and dropidol in patients receiving high dose interleukin-2
16. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens
17. Immunization with interleukin-2/interferon-γ double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma
18. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells
19. National survey of patterns of care for brain-tumor patients
20. Construction and use of a safe and efficient amphotropic packaging cell line
21. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations
22. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-α. Results of a phase I clinical trial
23. Liposomal transfection of human γ-interferon gene into human glioma cells and adoptive immunotherapy using lympohokine-activated killer cells
24. Rejection of mouse sarcoma cells after transfection of MHC class II genes
25. In vivo transfer of the human interleukin-2 gene: Negative tumoricidal results in experimental brain tumors
26. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
27. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
28. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor infiltrating lymphocytes
29. The epidemiology of central nervous system tumors
30. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors
31. RG-2 glioma growth attentuation and severe brain edema caused by local production of interleukin-2 and interferon-γ
32. Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma
33. Retroviral expression of the human IL-2 gene in a murine T cell line results in a cell growth autonomy and tumorigenicity
34. Treatment of glioma by engineered interleukin-4-secreting cells